Influence of marbofloxacin on the pharmacokinetics and pharmacodynamics of tolfenamic acid in calves
- 18 February 2005
- journal article
- Published by Wiley in Journal of Veterinary Pharmacology and Therapeutics
- Vol. 28 (1) , 109-119
Abstract
Pharmacokinetic and pharmacodynamic properties of tolfenamic acid (TA) in calves were determined in serum and fluids of inflamed (carrageenan administered) and non‐inflamed subcutaneously implanted tissue cages after intramuscular administration both alone and in combination with marbofloxacin (MB). MB significantly altered the pharmacokinetics of TA: mean values wereCmax = 2.14 and 1.64 μg/mL,AUC = 27.38 and 16.80 μg·h/mL, Vd(area)/F = 0.87 and 1.17 L/kg, and ClB/F = 0.074 and 0.128 L/kg/h, respectively, after administration of TA alone and TA + MB.T1/2K10and MRT were not significantly different for the two treatments. The pharmacodynamic properties of TA were not influenced by MB co‐administration, in spite of the alterations in some TA pharmacokinetic parameters. TA inhibited prostaglandin E2(PGE2) synthesisin vivoin inflammatory exudate by 50–88% for up to 48 h after both TA treatments. Inhibition of synthesis of serum thromboxane B2(TxB2)ex vivoranged from 40 to 85% up to 24 h after both TA and TA + MB. From the derived pharmacokinetic and eicosanoid inhibition data for TA, pharmacodynamic parameters for serum TxB2and exudate PGE2inhibition expressing efficacy (Emax = 78.1 and 97.5%), potency (IC50 = 0.256 and 0.265 μg/mL), sensitivity (N = 1.96 and 2.29) and the pharmacokinetic parameter equilibration time (t1/2Ke0 = 0.695 and 24.0 h), respectively, were determined. In this model TA was a nonselective inhibitor of cyclo‐oxygenase (COX) (COX‐1:COX‐2 IC50ratio = 1.37). TA, both alone and co‐administered with MB, did not affect leucocyte numbers in exudate, transudate or blood. Partial attenuation of skin temperature rise over inflamed tissue cages and reduction of zymosan‐induced skin swelling were recorded after administration of TA and TA + MB with no significant differences between the two treatments. These data provide a basis for the rational use of TA in combination with MB in calf medicine.Keywords
This publication has 47 references indexed in Scilit:
- Pharmacology of drugs used to treat osteoarthritis in veterinary practiceInflammopharmacology, 2003
- Pharmacokinetic and pharmacodynamic studies on phenylbutazone and oxyphenbutazone in goatsVeterinary Record, 1997
- Pharmacokinetics and pharmacodynamics of tolfenamic acid in calvesResearch in Veterinary Science, 1996
- Are tolfenamic acid and tenidap dual inhibitors of 5-lipoxygenase and cyclo-oxygenase?Inflammation Research, 1991
- Pharmacology and therapeutics of non‐steroidal anti‐inflammatory drugs in the dog and cat: 2 Individual agentsJournal of Small Animal Practice, 1991
- Pharmacokinetics of quinolones: Newer aspectsEuropean Journal of Clinical Microbiology & Infectious Diseases, 1991
- ABSTRACTEquine Veterinary Journal, 1991
- Orally administered tolfenamic acid inhibits leukotriene synthesis in isolated human peripheral polymorphonuclear leukocytesInflammation Research, 1989
- Understanding the Dose-Effect RelationshipClinical Pharmacokinetics, 1981
- Relation between morphine pharmacokinetics and analgesiaJournal of Pharmacokinetics and Biopharmaceutics, 1978